Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024

BOSTON, April 18, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that it intends to offer, subject to market and other conditions, $125 million aggregate principal amount of convertible senior subordinated notes due 2024. The notes will be offered and sold only to qualified institutional buyers in a private offering pursuant to Rule 144A under the Securities Act of 1933, as amended. Paratek also expects to grant the initial purchasers of the notes an option to purchase up to an additional $18.75 million aggregate prin…


Leave a Reply

Your email address will not be published.